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Abstract  Recent  advances  need  to  be  highlighted  in  the  management  of  both  localized  and
metastatic  prostate  cancer.  New  early  detection  and  molecular  characterization  tools  are  being
developed  to  improve  differentiation  of  their  progression  proﬁles  and  reduce  ‘‘overdetection’’
and ‘‘overtreatment’’  of  clinically  ‘‘insigniﬁcant’’  cancers.  In  addition,  the  development  of
multi-parametric  MR  has  improved  the  characterization  of  localized  cancer  and  introduced  the
new concept  of  focal  treatment.  Finally,  several  treatments  for  metastatic  cancer  which  is
resistant  to  castration  have  recently  increased  the  therapeutic  armamentarium.
© 2014  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
Signiﬁcant  advances  have  been  made  recently  and  more  will  be  made  in  the  coming  years
in  the  treatment  of  prostate  cancer.  The  ﬁrst  of  these  is  improved  detection  and  pretreat-
ment  characterization  based  on  targeted  multi-parametric  MR-guided  prostate  biopsies
and  the  development  of  new  biomarkers.  Secondly,  joint  advances  have  been  made  both
in  imaging  and  in  focal  treatments,  allowing  small  tumors  to  be  targeted  and  providing  as
effective  curative  treatment  as  radical  therapy  but  without  its  adverse  effects.  Finally,  new
treatments  for  metastatic  cancer  which  is  resistant  to  castration  have  been  developed.
Detection and characterization: new RNA markersThe  limitations  of  the  screening  tools,  the  major  one  of  which  is  serum  prostate-
speciﬁc  antigen  (PSA),  have  been  widely  demonstrated.  The  negative  predictive  value
of  PSA  is  only  85%  and  75%  of  patients  investigated  for  a  PSA  level  of  between  2.5
Abbreviations: AS, Aortic Stenosis; ATU, Temporary Authorization For Use; HIFU, High Intensity Focused Ultrasound; MA, Marketing
Authorization; PDT, PhotoDynamic Therapy; PSA, Prostate-Speciﬁc Antigen; VTP, Vascular Targeting PDT.
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nd  10  ng/mL  (and/or  pathological  rectal  examination)  have
egative  biopsies  [1].  Conversely,  10  to  35%  of  these  patients
re  subsequently  diagnosed  with  a  prostatic  adenocarci-
oma  from  repeat  biopsies.  The  use  of  age-related  PSA
elocity  (PSAv)  and  density  (PSAd),  complexed  PSA  (PSAc)
nd  the  free/total  PSA  ratio  have  only  brought  marginal
mprovements  in  diagnosis.  These  limitations  feed  into  the
ebate  about  the  appropriateness  of  mass  screening  for
rostate  cancer,  although  this  has  shown  to  reduce  disease-
peciﬁc  mortality  by  20%,  but  have  also  highlighted  the  risk
f  overdiagnosis  and  overtreatment.
A  number  of  the  biomarkers  currently  under  evaluation
re  markers  of  RNA  expression.  Some  of  these,  such  as  the
CA3  gene  or  TMPRSS2  and  ETS  gene  fusion  transcripts,  can
e  detected  in  urine.  Others  represent  the  ‘‘tumor  tissue
xpression  signature’’  of  gene  panels.
The  PCA3, or  differential  display  code  3  (DD3)  gene  is
ocated  on  9q21-22.  It  is  almost  invariably  overexpressed  in
rostate  tumor  tissue,  by  a  factor  of  66  to  140  times  more
han  in  non-malignant  prostate  tissue  [2]  and  is  non-existent
n  non-prostatic  healthy  tissue  and  in  other  cancers.
Five  single  or  multicenter  prospective  studies  have  pub-
ished  the  results  of  a  urinary  PCA3  test  in  unselected
atients  who  have  undergone  prostatic  biopsies  because
f  a  raised  PSA  (threshold  2.5  to  4  ng/mL)  and/or  have
n  abnormal  rectal  examination  [3,4].  These  studies  have
emonstrated  the  PCA3  score  to  be  superior  to  PSA  mea-
urement  (total  and/or  free),  in  terms  of  predictive  value
positive  or  negative)  and  speciﬁcity,  at  the  cost  of  slightly
ower  sensitivity.  The  cut  points  of  35  appears  to  be  the  most
iscriminatory.  The  PCA3  score  still  performs  well  regardless
f  PSA  levels  (less  than  4  to  10,  or  over  10  ng/mL)  or  prostate
olume  [3,4].
Three  series  have  recently  examined  the  correlation
etween  the  preoperative  PCA3  score  and  factors  relating  to
umor  aggression  and  volume  on  prostatectomy  specimens
5,6].
The  TMPRSS2-ETS  fusion  genes  have  been  demonstrated
n  the  majority  of  cases  of  prostate  cancer.  The  most
sual  variant  involves  two  genes  located  on  chromosome
1,  TMPRSS2  and  ERG. The  TMPRSS2  gene  codes  for  trans-
embrane  serum  protease  2  which  is  strongly  expressed  by
ormal  and  malignant  prostate  cells  and  its  expression  is
egulated  by  androgens.  Genes  belonging  to  the  ETS  fam-
ly  (ERG, ETV1, ETV4) code  for  transcription  factors  which
re  involved  in  the  signaling  pathways  which  regulate  cell
rowth,  cell  differentiation  and  carcinogenesis.  Activation
f  the  ERG  by  fusion  with  TMPRSS2  under  the  inﬂuence  of
ndrogen  stimulation  appears  to  be  responsible  for  over-
xpression  of  transcription  factors,  which  may  result  in
pigenetic  reprogramming  and  dysregulation  of  the  apopto-
is  pathways.  The  different  isoforms  of  the  fusion  genes  and
heir  level  of  expression  may  also  inﬂuence  tumor  progres-
ion  [7].  Detection  of  gene  transcripts  in  urine  is  however
ifﬁcult  and  reported  detection  rates  are  around  50%.  Com-
ined  detection  methods  in  urine  before  and  after  biopsy
nd  in  the  biopsy  gun  rinse  material  are  currently  being
ssessed  [8].Combined  assessment  of  the  tissue  expression  of  genes
nvolved  individually  in  cancer  progression  has  been  used
o  study  ‘‘gene  expression  signatures’’.  Several  tools  have
een  developed  in  this  context  and  are  under  assessment.  As
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n  example,  CPP  (cell-cycle  progression  gene  Panel)  repre-
ents  the  expression  proﬁle  of  31  genes  involved  in  cellular
roliferation  [9].  Tumor  tissue  expression  of  these  genes
s  reported  as  a  score.  Several  retrospective  assessment
tudies  have  suggested  that  the  CPP  score  is  independently
ssociated  with  biologic  recurrence  and  disease-speciﬁc
urvival  after  radical  prostatectomy  [9],  including  disease-
peciﬁc  survival  in  patients  included  in  active  monitoring
rotocols  [10].
ocal treatments: photodynamic
aporization
nlike  in  other  tumor  models  (breast,  cervix  and  colon
tc.),  the  early  diagnosis  and  screening  for  prostate  can-
er  do  not  at  present  alter  the  treatment  target  which
emains  the  entire  gland.  In  a  small,  still  limited  tumor,  the
ost  satisfactory  approach,  however,  theoretically,  would
e  local  treatment.  The  sine  qua  non  condition  for  this  is
rstly  that  these  small  tumors  are  well-visualized.  Diffusion-
eighted  MR  and  spectrometry  currently  allow  cancers  with
 volume  of  0.50  cc  or  more,  to  be  diagnosed.  These  inves-
igations  are  becoming  increasingly  reliable  and  consistent
ndings  are  generally  achieved  between  imaging  and  the
urgical  specimens  or  histology  results.  As  prostate  tumors
re  often  multifocal,  the  index  site  which  determines  the
otential  of  the  tumor  to  progress  needs  to  be  identiﬁed
nd  targeted.  This  would  appear  sufﬁcient  to  signiﬁcantly
educe  overall  tumor  volume  and  delay  progression  [11].
his  is  the  principle  on  which  uni-  or  even  bifocal  treat-
ent  is  based.  Different  techniques  can  be  used  for  this
nd  are  described  in  several  recent  publications  [12—14]:
igh  intensity  focal  ultrasound  (HIFU),  cryotherapy,  laser
hototherapy,  radiofrequency  ablation,  local  curietherapy
nd  stereotactic  radiotherapy.  The  aim  of  these  is  to  offer
elatively  non-invasive  treatments  which  do  not  have  the
dverse  effects  of  radical  surgery  (impotence  and  inconti-
ence),  but  which  also  do  not  compromise  the  success  of
ubsequent  treatments.  The  key  factor  is  not  to  prevent
everting  to  radical  or  salvage  treatment  if  required.  There
s  as  yet  insufﬁciently  long  clinical  experience  with  these
ethods  to  establish  whether  the  local  treatments  impact
n  subsequent  therapies.  Photodynamic  vaporization  may  be
ess  prone  to  this,  although  it  is  still  far  too  early  to  draw
onclusions.
Photodynamic  vaporization  (or  vascular  targeting  pho-
otherapy,  VTP)  is  a developing  technique  for  the  curative
reatment  of  solid  cancers.  PDT  is  currently  used  and
as  been  developed  in  gastroenterology,  dermatology  and
NT  practice  and  in  gynecology  [15]. This  involves  light
ctivation  of  an  intravenously  injected  photosensitizing
gent.  Very  short  half-life  photosensitizing  agents  which
re  activated  intravascularly  have  recently  been  developed
nd  include  padoporﬁn  or  padeliporﬁn  (WST11  or  Tookad
oluble®).  Activation  of  WST1  by  a  753  nm  laser  light  source
auses  tumor  ischemia  due  to  vasoconstriction  and  endothe-
ial  lysis.  The  tumor  is  illuminated  by  optical  ﬁbers  with  a
iffusing  tip  which  are  introduced  across  the  perineum  under
ltrasound  guidance.  The  energy  delivered  to  the  tissues  can
e  calculated  based  on  the  diffusion  surface  area  of  the  tip
f  the  optical  ﬁber.  This  is  the  light  ﬂuency,  expressed  in
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joules  per  square  centimeter  (J/cm2).  The  number  of  ﬁbers
to  be  introduced,  their  sites  and  the  length  of  their  diffusing
tip,  are  determined  preoperatively  by  MRI.
Three  phase  II  studies  have  suggested  that  this  tech-
nique  is  both  feasible  and  well-tolerated  (PCM  studies  201,
202  and  203).  The  negative  biopsy  rate  at  6  months  in  the
treated  area  was  over  80%  after  optimal  treatment  (LDI  >  1)
and  its  impact  on  erectile  function  was  minor  or  insignif-
icant.  Seventeen  of  the  121  patients  treated  underwent
radical  treatment  during  their  follow-up  (5  had  curiether-
apy  and  12  underwent  radical  prostatectomy)  after  a  median
period  of  21  months.  The  authors  did  not  report  any  partic-
ular  technical  difﬁculties  during  the  procedures.  Functional
and  oncological  assessments  of  a  larger  number  of  patients,
however,  are  needed  in  order  to  assess  the  effects  of  rad-
ical  treatments  after  PDT.  A  phase  III  study  is  ongoing  in
Europe  (PCM  301),  comparing  PDT  with  active  monitoring.
The  primary  objective  of  this  study  is  time  to  oncolo-
gical  progression  and  the  results  will  be  available  in  a
few  months.
New therapies against castration-resistant
prostate cancer
In  clinical  practice,  CRPC  (castration-resistant  prostate  can-
cer)  is  deﬁned  as  a  total  serum  testosterone  of  under
0.5  ng/mL  (or  1.7  nmol/L)  with  three  successive  increases
in  PSA,  over  minimum  intervals  of  one  week  [16].  To  date,
docetaxel  chemotherapy  at  a  dose  of  75  mg/m2 every  three
weeks  combined  with  10  mg/day  of  prednisone,  continued
androgen  suppression  and  supportive  care,  is  the  standard
treatment  [17].  This  treatment  regimen  will  shortly  change
as  a  result  of  the  arrival  of  new  treatments  which  have
been  shown  to  be  effective  in  terms  of  increased  over-
all  survival  compared  to  placebo  (comfort  care  including
continued  androgen  suppression).  Speciﬁcally,  these  include
the  new  hormone  therapies  (abiraterone,  TAK-700  and  MDV
3100).
Abiraterone  acetate  (Zytiga®)  is  a  selective  inhibitor  of
androgen  biosynthesis  which  blocks  cytochrome  P450  c17
(CYP17),  a  key  enzyme  in  the  production  of  testosterone.
Androgen  production  by  the  adrenal  gland,  testes  and  tumor
cells  is  therefore  inhibited  [18],  as  is  production  within
the  tumor.  The  dose  used  is  1  g/day  (4  ×  250  mg  tablets).
In  the  pivot  study  [19],  1195  patients  were  randomized
to  abiraterone  combined  with  prednisone  (797  patients)
or  placebo  combined  with  prednisone  (398  patients)  on  a
double-blind  basis  after  failure  of  docetaxel  therapy.  The
primary  end  point  was  improvement  in  overall  survival.
After  a  median  follow-up  period  of  12.8  months,  overall  sur-
vival  was  in  favor  of  abiraterone  (14.8  months  compared
to  10.9  months;  HR  =  0.65;  95%  CI:  0.54  to  0.77;  P  <  0.001).
In  addition,  all  of  the  secondary  end  points  (progression  of
PSA,  time  to  progression  and  the  fall  in  PSA)  favored  abi-
raterone.  The  most  common  adverse  effects  were  back  pain
(30%),  nausea  (30%),  constipation  (26%),  bone  pain  (25%)  and
arthralgia  (25%).  Abiraterone  has  recently  obtained  market-
ing  authorization  in  France.  Another  medicinal  product  with
an  identical  mechanism  of  action,  TAK-700  (orteronel),  is
currently  being  assessed  in  a  phase  III  study  [20].741
MDV  3100  is  a  new  AR  signaling  pathway  inhibitor.  It  is
 competitive  inhibitor  of  the  AR  which  partially  prevents
ts  nuclear  translocation  and  a priori  completely  prevents  it
inding  to  DNA.  In  the  phase  III  study  (the  AFFIRM  study)  [21],
199  patients  were  randomized  to  receive  160  mg/day  of
DV,  3100  compared  to  a  placebo  before  or  after  chemother-
py.  After  520  deaths,  the  interim  analysis  of  overall  survival
as  signiﬁcantly  better  in  the  treatment  arm  (18.4  months
ompared  to  13.6;  HR  =  0.63;  P  <  0.0001)  conferring  a  median
ain  in  survival  of  4.8  months,  or  a  37%  reduction  in  mortal-
ty.  MDV  has  not  yet  obtained  MA  and  will  be  available  as  a
emporary  authorization  for  use  (ATU)  in  the  coming  months.
ts  most  common  adverse  effects  have  been  fatigue  (33%),
ausea  (33%),  anorexia  (25%),  constipation  (24%)  and  back
ain  (24%),  although  there  was  no  difference  between  the
reatment  and  placebo  arms.
TAKE-HOME  MESSAGES
• A  high  urinary  PCA3  score  is  associated  with  clinically
signiﬁcant  cancer.
• Combined  use  of  molecular  markers  such  as  the
PCA3  score  and  fusion  transcripts  appear  to  improve
pretreatment  characterization  of  the  prostate
cancer.
• Photodynamic  vaporization  of  the  prostate  gland
is  a local  transperineal  treatment  producing
circumscribed  necrosis  of  the  index  tumor.
• Abiraterone  acetate  is  a  selective  inhibitor  of  an
androgen  biosynthesis  enzyme,  which  is  indicated
for  use  in  metastatic  cancer  which  is  resistant  to
castration  before  or  after  docetaxel  chemotherapy.
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